Format

Send to

Choose Destination
Curr Opin Pharmacol. 2008 Oct;8(5):574-81. doi: 10.1016/j.coph.2008.04.009. Epub 2008 Jun 12.

Recent advances in bacterial topoisomerase inhibitors.

Author information

1
Achillion Pharmaceuticals, Inc., 300 George Street, New Haven, CT 06511, USA. bbradbury@achillion.com

Abstract

Bacterial topoisomerase inhibitors continue to be actively developed as clinical antibacterial agents, largely owing to the success of the currently marketed inhibitors, the quinolones, and the increasing resistance to these agents. New quinolone analogs such as isothiazoloquinolones and quinazolinediones show some potential in overcoming this problem. Quinolones linked to other antibacterial agents such as rifamycins and oxazolidinones are designed to overcome both quinolone-specific resistance and resistance to the coupled agents. Novel inhibitors targeting non-quinolone-binding regions of topoisomerase continue to expand beyond the known coumarin class. The benzimidazoles and pyrazoles have shown promise but have been surpassed into the clinic by novel quinolines. Improved screening techniques and high-throughput methods offer new hope of further expanding the chemical space of topoisomerase inhibitors.

PMID:
18555745
DOI:
10.1016/j.coph.2008.04.009
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center